Corporate Presentation

Revolutionizing Vaccines

Dr. J. Joseph Kim President & CEO NYSE MKT: INO

Forward Looking Statement

Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013 and other regulatory filings from time to time.

2

3

2013: Dynamic Year • Best T cell responses in published clinical studies • Validating license deal with Roche in 2013

• $10 mm up-front, all development costs, $412.5 mm in milestones, plus royalties

2014: Transformative Year • Phase II efficacy data from lead drug mid-year • More cancer trials starting (cervical, head & neck, prostate,

breast, lung) • Additional pharma deals in the works

Inovio: Global Leader in Active Immune Therapy

4

Empowering Our Own Immune System to Defeat Disease

• Key player in effective immune therapy

• Kills tumors and infected cells • Are safe and tolerable

• Requires a directive to attack

T cells: Inovio Commands the Body’s SWAT Team

T cell Cytotoxic T lymphocyte

Target cell

5

T cells: Inovio Commands the Body’s SWAT Team

T cell Cytotoxic T lymphocyte

Target cell

Provided by Dr. Philip Greenberg Hutchinson Cancer Research Center

6

Recent PD-1 Clinical Data Validation: T cells All-Important in Immune Therapy

7

PD-1

PD-L1 Cancer cell

T cell

Passive Immune Therapy: Checkpoint Inhibitors

8

Passive

PD-1 Therapy

Checkpoint inhibitor

T cell

Passive Immune Therapy: Checkpoint Inhibitors

PD-1

PD-L1

9

Validation of Inovio’s aggressive T cell therapy

Active Immune Therapy: Inovio Therapeutic Vaccines

10

Best-in-class T cells with powerful killing effect

Active

T cells are the key to clinical outcome

Active Immune Therapy: Inovio Therapeutic Vaccines

11

12

Inovio: Leader in Active Cancer Immunotherapies

• Inovio cancer vaccines: Potential to increase efficacy

• Cervical/head & neck cancers • Breast cancer • Lung cancer • Pancreatic cancer • Melanoma • Prostate cancer

• Potential to improve safety and tolerability

• Major products in multi-billion market

• Unprecedented efficacy

• Melanoma • Lung cancer • Others

• Efficacy can be improved by

combining with active cancer vaccines

• Concerns about safety and tolerability signals

• Projected to be a $24 billion market

Powerful Combination of Active and Passive Immune Therapy

13

Inovio’s Technology

Plasmids

Electroporation device

• Synthetic DNA vaccines highly optimized for antigen expression

• SynCon® sequences designed to break tolerance or provide universal protection

• CELLECTRA® electroporation ideal delivery of DNA vaccines

• Best-in-class immune responses

• Favorable safety profile • Over 400 patents

Inovio’s Technology

14

#1 in Generating and Driving T Cell Responses in People

15

VGX-3100: Phase I Study Data

• Strong T-cell response in 14 of 18 (78%) vaccinated subjects at month 4

• 83% response rate in highest dose group

*Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct; 4:155ra13. dOI:10.1126/scitranslmed.3004414

VGX-3100 Demonstrated Best In Class T cell Responses

16

• 9 month durability of robust T cell response in 12/14 responders

• Safe & well tolerated

Source: Science Translational Medicine Oct. 2012 17

• 10/11 responders showed killing effect against target cells

Durable T cell Responses and T Cell Killing Effects

PENNVAX® HIV Vaccine: Highest CD8+ T cell Responses

Ref: Kalams et al JID 2013

18

A: 3X vaccination without EP B: 4X vaccination without EP C: 2x vaccination with EP (month 2) D: 3x vaccination with EP (month 4) E: Memory response (month 9)

A B C D E

Broad Medical and Market Opportunities

Product Name

INTERNALLY FUNDED

Indication Preclinical Phase I Phase II

Vgx-3100

Ino-5150

Ino-1400

EXTERNALLY FUNDED

pennvax®

Ino-3510

Ino-8000

ino-1800

malaria MaV-12

Phase III

Preventive

19

INO-3112

INO-3112

Preventive

Hepatitis C Therapeutic

Hepatitis B Therapeutic

influenza

Preventive

hiv

Preventive/Th

erapeutic

Breast/lung cancers

Therapeutic

Prostate cancer Therapeutic

Head & Neck Cancer Therapeutic

Cervical Cancer Therapeutic

Cervical dysplasia

Therapeutic

Inovio’s Lead Program

VGX-3100: • Capitalizes on Inovio’s ability to generate T cells • Immunotherapy for pre-cancers and cancers caused by

human papillomavirus (HPV) • Phase II on-going: high grade cervical pre-cancers (CIN

2/3 dysplasia) • Projected efficacy data: mid-2014

20


21

22


Broad Medical and Market Opportunities

HPV product franchise planning • CIN 2/3 phase III • Other HPV-related indications (cervical cancer and head/neck

cancer): initiate phase II studies • Orphan designation potential

23

INO-1400: Potential Universal Cancer Therapy

Yan J et al., Cancer Immunol Res. (2013) 24

25

Broad Base of Support for Inovio

Almost $60M in non-dilutive funding since 2009

Power of our People

• Management • Board of Directors • Scientific Advisory Board

26

Louis Pasteur

Peter Kies CFO • Ernst & Young • Experience with growth companies

Mark L. Bagarazzi, MD CMO • Clinical research experience incl. Merck • Led clinical/regulatory for shingles and rotavirus vaccines; DNA vaccine expert

27

J.Joseph Kim, PhD President & CEO

• Decades of biotechnology/pharma management

• Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D

Niranjan Y. Sardesai, PhD COO

• Extensive biotech management and product development experience

• Led development of diagnostics for mesothelioma, bladder cancer, and ovarian

cancer for Fujirebio Diagnostics

Management

Louis Pasteur J.Joseph Kim, PhD • President & CEO, Inovio

Adel Mahmoud, PhD • Professor, Princeton University • Former President, Merck Vaccines • Responsible for Gardasil®, Zostavax®, Proquad® and Rotateq®

Morton Collins, PhD • General Partner, Battelle Ventures and Innovations Valley Partners

28

Simon X. Benito • Former Senior Vice President,

Merck Vaccine Division

Angel Cabrera, PhD • President, George Mason University

• Former President, Thunderbird School of Global Management

Avtar Dhillon, MD Chairman, BOD

• Former President & CEO, Inovio Biomedical

Board of Directors

Louis Pasteur Stanley A. Plotkin, MD • Developed rubella and rabies vaccines • Oversaw Sanofi flu vaccine • Emeritus Professor, Wistar Institute & University of Pennsylvania

Philip Greenberg, MD • Expert in T-cell immunology • Head, Immunology Program, Fred Hutchinson Cancer Research Center

29

Thomas S. Edgington, MD • Founded multiple biotech companies;

extensively published • Emeritus Professor, Scripps

Research Institute

Anthony W. Ford-Hutchinson, PhD • Former SVP, Vaccines R&D, Merck

• Oversaw development: Singulair®, Januvia®, Gardasil®, Zostavax®, Proquad® and Rotateq®

David B. Weiner, PhD Chairman

•“Father of DNA vaccines” • Dept. of Pathology & Laboratory Medicine,

University of Pennsylvania

Scientific Advisory Board

30

2/1/13 3/1/13 4/1/13 5/1/13 6/1/13 7/1/13 8/1/13 9/1/13 10/1/13 11/1/13 12/1/13 1/1/14 2/1/14

Stock Price

Financial Information

Cash, cash equivalents & short-term investments1 $ 46.3 M

Debt1 0 M

Cash runway 1Q 2016

Issued & outstanding shares2 211.4 M

Recent price3 $2.49

Market cap3 $526.4 M

NYSE MKT: INO

1Sep. 30, 2013 3 Feb 3, 2014 31

Additional cash4 $ 11.1 M

2Jan 31, 2014 4 Nov 12, 2013

Upcoming Value Drivers

32

INTERNALLY FUNDED EXTERNALLY FUNDED

Ino-5150 1H 2014 Initiate phase I/IIa Prostate cancer

Vgx-3100

Mid-2014 Phase II study data Cervical dysplasia

INO-3112

1H 2014 Initiate phase I/IIa

Head & Neck Cancer

33


INO-3112

1H 2014 Initiate phase I/IIa

Cervical Cancer

Ino-1400

2014 Initiate phase I/IIa

Breast/lung Cancer

INTERNALLY FUNDED EXTERNALLY FUNDED

PennVAX2014 Initiate PENNVAX -GP phase I study HIV

Ino-8000

2015 Report phase I data Hepatitis C

MAV-12

2014 Initiate phase I/IIa

Malaria

34


Ino-1800

2014 Prepare phase I/IIa Hepatitis B

Investor Highlights • Break-through active immune therapy with the

power to save lives and maximize shareholder value

• Targeting broad range of diseases and billion dollar markets • Best-in-class T cells to prevent, treat & cure cancers and infectious diseases

• Phase II efficacy data coming

• Validating partnership with Roche with more deals in the works

The Opportunity

35

Bernie Hertel Senior Director, Communications & Investor Relations 858-410-3101 [email protected]

Investor Contact

Investor Contact

36

Corporate Presentation

Documents

Transcript of Corporate Presentation